サイトメガロウイルス(CMV)治療の世界市場2019-2023

◆英語タイトル:Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023
◆商品コード:IRTNTR31041
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年3月29日
◆ページ数:121
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、サイトメガロウイルス(CMV)治療の世界市場について調査・分析し、市場概要、市場環境、サイトメガロウイルス(CMV)治療市場規模、投与経路別(口腔、非経口、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・サイトメガロウイルス(CMV)治療の世界市場概要
・サイトメガロウイルス(CMV)治療の世界市場環境
・サイトメガロウイルス(CMV)治療の世界市場動向
・サイトメガロウイルス(CMV)治療の世界市場規模
・サイトメガロウイルス(CMV)治療の世界市場:業界構造分析
・サイトメガロウイルス(CMV)治療の世界市場:投与経路別(口腔、非経口、その他)
・サイトメガロウイルス(CMV)治療の世界市場:地域別市場規模・分析
・サイトメガロウイルス(CMV)治療の北米市場規模・予測
・サイトメガロウイルス(CMV)治療のヨーロッパ・中東・アフリカ市場規模・予測
・サイトメガロウイルス(CMV)治療のアジア太平洋市場規模・予測
・サイトメガロウイルス(CMV)治療の主要国分析
・サイトメガロウイルス(CMV)治療の世界市場:成長要因、課題
・サイトメガロウイルス(CMV)治療の世界市場:競争環境
・サイトメガロウイルス(CMV)治療の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
High prevalence of congenital CMV will drive the CMV therapeutics market growth in the forthcoming years. Vendors are increasingly conducting researches to launch novel therapeutics including vaccines that can be administered in newborns. This will also prevent the progression of CMV while catering to the huge unmet need in the market. As a result, the high prevalence of congenital CMV will eventually drive the CMV therapeutics market growth during the next few years. Technavio’s analysts have predicted that the cytomegalovirus (CMV) therapeutics market will register a CAGR of nearly 5% by 2023.
Market Overview
Recurring nature of the disease
One of the growth drivers of the global cytomegalovirus (CMV) therapeutics market is the recurring nature of the disease. The recurring nature of CMV and the potential risk of the indications caused by the disease will significantly increase sales of CMV therapeutics, which will drive the growth of the market.
Asymptomatic nature of the disease
One of the challenges in the growth of the global cytomegalovirus (CMV) therapeutics market is the asymptomatic nature of the disease. The poor diagnosis rate of the disease is expected to hinder the growth of the market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the cytomegalovirus (CMV) therapeutics market during 2019-2023, view our report.
Competitive Landscape
The market appears to be highly concentrated with the presence of a few market players. Vendors in the market are focusing on developing drugs in more than one form to provide treatment options and ensure the high efficacy of their drugs. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY ROA
• Market segmentation by RoA
• Comparison by RoA
• Oral – Market size and forecast 2018-2023
• Parenteral – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by RoA
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Bausch Health
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• Merck & Co., Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Global CMV therapeutics market pipeline: Overview
Exhibit 18: Global CMV therapeutics market pipeline: Overview
Exhibit 19: RoA – Market share 2018-2023 (%)
Exhibit 20: Comparison by RoA
Exhibit 21: Oral – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral – Year-over-year growth 2019-2023 (%)
Exhibit 23: Parenteral – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Parenteral – Year-over-year growth 2019-2023 (%)
Exhibit 25: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others – Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by RoA
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AstraZeneca – Vendor overview
Exhibit 52: AstraZeneca – Product segments
Exhibit 53: AstraZeneca – Organizational developments
Exhibit 54: AstraZeneca – Geographic focus
Exhibit 55: AstraZeneca – Key offerings
Exhibit 56: AstraZeneca – Key customers
Exhibit 57: Bausch Health – Vendor overview
Exhibit 58: Bausch Health – Business segments
Exhibit 59: Bausch Health – Organizational developments
Exhibit 60: Bausch Health – Geographic focus
Exhibit 61: Bausch Health – Segment focus
Exhibit 62: Bausch Health – Key offerings
Exhibit 63: Bausch Health – Key customers
Exhibit 64: F. Hoffmann-La Roche Ltd – Vendor overview
Exhibit 65: F. Hoffmann-La Roche Ltd – Business segments
Exhibit 66: F. Hoffmann-La Roche Ltd – Organizational developments
Exhibit 67: F. Hoffmann-La Roche Ltd – Geographic focus
Exhibit 68: F. Hoffmann-La Roche Ltd – Segment focus
Exhibit 69: F. Hoffmann-La Roche Ltd – Key offerings
Exhibit 70: F. Hoffmann-La Roche Ltd – Key customers
Exhibit 71: Gilead Sciences, Inc. – Vendor overview
Exhibit 72: Gilead Sciences, Inc. – Business segments
Exhibit 73: Gilead Sciences, Inc. – Organizational developments
Exhibit 74: Gilead Sciences, Inc. – Geographic focus
Exhibit 75: Gilead Sciences, Inc. – Key offerings
Exhibit 76: Gilead Sciences, Inc. – Key customers
Exhibit 77: Merck & Co., Inc. – Vendor overview
Exhibit 78: Merck & Co., Inc. – Business segments
Exhibit 79: Merck & Co., Inc. – Organizational developments
Exhibit 80: Merck & Co., Inc. – Geographic focus
Exhibit 81: Merck & Co., Inc. – Segment focus
Exhibit 82: Merck & Co., Inc. – Key offerings
Exhibit 83: Merck & Co., Inc. – Key customers
Exhibit 84: Validation techniques employed for market sizing



【掲載企業】

AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Merck & Co., Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[サイトメガロウイルス(CMV)治療の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆